宣布MedComm -未来医学:一个将未来带到现在的论坛

Robin Ali, Michael Karin, Kang Zhang
{"title":"宣布MedComm -未来医学:一个将未来带到现在的论坛","authors":"Robin Ali,&nbsp;Michael Karin,&nbsp;Kang Zhang","doi":"10.1002/mef2.13","DOIUrl":null,"url":null,"abstract":"<p>We are entering a new and exciting era of medicine. New technological advances in artificial intelligence (AI), multiomics and regenerative medicine bring unprecedented promise to the realization of personalized medicine. The future of medicine and the future of healthcare are dependent on the translation of these innovations into new diagnostics and therapeutics which could profoundly impact patient care delivery. We are therefore delighted and proud to launch <i>MedComm – Future Medicine</i>, a new Wiley journal. <i>MedComm – Future Medicine</i> is an open-access journal which will publish the latest and most impactful biomedical research. We are a multidisciplinary journal with special interest in multiomics, bioinformatics, medical AI, stem cell and regenerative medicine, and gene therapy. Our articles in medicine and biology will be reviewed and assessed on the basis of novelty, timeliness and significance to human health and diseases. We will cover the latest advances in biomedical research that improve our understanding of diseases, address unmet medical needs, and have the potential to transform healthcare.</p><p>We have assembled a world-class editorial board, led by our Editors-In-Chief Professor Robin Ali, Professor Michael Karin, and Professor Kang Zhang. The editorial board members consist of an international group of leading experts in their research domains. Our mission at the editorial board is to ensure your best research is subjected to the highest quality and rigorous peer-review in a timely fashion. We also have dedicated editorial staff who co-ordinate the peer review process, production of your accepted articles and marketing of <i>MedComm – Future Medicine</i>. We will ensure that your paradigm-shifting discoveries will receive the highest quality production, and reach the widest readership.</p><p><i>MedComm – Future Medicine</i> is born at a time of global healthcare emergency. The Covid-19 pandemic has put into focus the importance of international collaborative efforts, which have resulted in an unprecedented increase in research output. Effective review and dissemination of this information is indispensable to maximizing research impact and public engagement. <i>MedComm – Future Medicine</i> aspires to be at the nexus of translational research advances. The success of <i>MedComm – Future Medicine</i> will be a testament to the global community of scientists and researchers who contribute to the journal's contents, review process and citations. We hope you will enjoy reading our contents and consider submitting your next paradigm-shifting research findings to <i>MedComm – Future Medicine</i>. Together, we hope to transform the future of medicine!</p>","PeriodicalId":74135,"journal":{"name":"MedComm - Future medicine","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/mef2.13","citationCount":"0","resultStr":"{\"title\":\"Announcing MedComm – Future Medicine: A forum to bring the future to the present\",\"authors\":\"Robin Ali,&nbsp;Michael Karin,&nbsp;Kang Zhang\",\"doi\":\"10.1002/mef2.13\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>We are entering a new and exciting era of medicine. New technological advances in artificial intelligence (AI), multiomics and regenerative medicine bring unprecedented promise to the realization of personalized medicine. The future of medicine and the future of healthcare are dependent on the translation of these innovations into new diagnostics and therapeutics which could profoundly impact patient care delivery. We are therefore delighted and proud to launch <i>MedComm – Future Medicine</i>, a new Wiley journal. <i>MedComm – Future Medicine</i> is an open-access journal which will publish the latest and most impactful biomedical research. We are a multidisciplinary journal with special interest in multiomics, bioinformatics, medical AI, stem cell and regenerative medicine, and gene therapy. Our articles in medicine and biology will be reviewed and assessed on the basis of novelty, timeliness and significance to human health and diseases. We will cover the latest advances in biomedical research that improve our understanding of diseases, address unmet medical needs, and have the potential to transform healthcare.</p><p>We have assembled a world-class editorial board, led by our Editors-In-Chief Professor Robin Ali, Professor Michael Karin, and Professor Kang Zhang. The editorial board members consist of an international group of leading experts in their research domains. Our mission at the editorial board is to ensure your best research is subjected to the highest quality and rigorous peer-review in a timely fashion. We also have dedicated editorial staff who co-ordinate the peer review process, production of your accepted articles and marketing of <i>MedComm – Future Medicine</i>. We will ensure that your paradigm-shifting discoveries will receive the highest quality production, and reach the widest readership.</p><p><i>MedComm – Future Medicine</i> is born at a time of global healthcare emergency. The Covid-19 pandemic has put into focus the importance of international collaborative efforts, which have resulted in an unprecedented increase in research output. Effective review and dissemination of this information is indispensable to maximizing research impact and public engagement. <i>MedComm – Future Medicine</i> aspires to be at the nexus of translational research advances. The success of <i>MedComm – Future Medicine</i> will be a testament to the global community of scientists and researchers who contribute to the journal's contents, review process and citations. We hope you will enjoy reading our contents and consider submitting your next paradigm-shifting research findings to <i>MedComm – Future Medicine</i>. Together, we hope to transform the future of medicine!</p>\",\"PeriodicalId\":74135,\"journal\":{\"name\":\"MedComm - Future medicine\",\"volume\":\"1 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-06-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/mef2.13\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"MedComm - Future medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/mef2.13\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"MedComm - Future medicine","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/mef2.13","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

我们正在进入一个令人兴奋的医学新时代。人工智能(AI)、多组学和再生医学的新技术进步为实现个性化医疗带来了前所未有的希望。医学和医疗保健的未来取决于将这些创新转化为新的诊断和治疗方法,这可能会对患者的护理产生深远的影响。因此,我们很高兴和自豪地推出MedComm -未来医学,一个新的威利杂志。《MedComm -未来医学》是一本开放获取的杂志,将发表最新和最具影响力的生物医学研究。我们是一本多学科期刊,特别关注多组学,生物信息学,医学人工智能,干细胞和再生医学以及基因治疗。我们在医学和生物学方面的文章将根据新颖性、时效性和对人类健康和疾病的重要性进行审查和评估。我们将涵盖生物医学研究的最新进展,这些研究提高了我们对疾病的理解,解决了未满足的医疗需求,并有可能改变医疗保健。我们组建了一个世界级的编委会,由主编Robin Ali教授、Michael Karin教授和张康教授领导。编委会成员由各自研究领域的国际领先专家组成。我们在编辑委员会的使命是确保您最好的研究及时受到最高质量和严格的同行评审。我们也有专门的编辑人员,他们负责协调同行评议过程、您接受的文章的制作和MedComm - Future Medicine的营销。我们将确保您的范式转换的发现将得到最高质量的生产,并达到最广泛的读者群。MedComm -未来医学在全球医疗紧急情况下诞生。2019冠状病毒病大流行凸显了国际合作的重要性,研究成果取得了前所未有的增长。有效地审查和传播这些信息对于最大限度地发挥研究影响和公众参与是必不可少的。MedComm -未来医学渴望成为转化研究进步的纽带。《MedComm -未来医学》的成功将是全球科学家和研究人员为该杂志的内容、评审过程和引用做出贡献的证明。我们希望您喜欢阅读我们的内容,并考虑将您的下一个范式转变的研究成果提交给MedComm -未来医学。我们希望一起改变医学的未来!
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Announcing MedComm – Future Medicine: A forum to bring the future to the present

We are entering a new and exciting era of medicine. New technological advances in artificial intelligence (AI), multiomics and regenerative medicine bring unprecedented promise to the realization of personalized medicine. The future of medicine and the future of healthcare are dependent on the translation of these innovations into new diagnostics and therapeutics which could profoundly impact patient care delivery. We are therefore delighted and proud to launch MedComm – Future Medicine, a new Wiley journal. MedComm – Future Medicine is an open-access journal which will publish the latest and most impactful biomedical research. We are a multidisciplinary journal with special interest in multiomics, bioinformatics, medical AI, stem cell and regenerative medicine, and gene therapy. Our articles in medicine and biology will be reviewed and assessed on the basis of novelty, timeliness and significance to human health and diseases. We will cover the latest advances in biomedical research that improve our understanding of diseases, address unmet medical needs, and have the potential to transform healthcare.

We have assembled a world-class editorial board, led by our Editors-In-Chief Professor Robin Ali, Professor Michael Karin, and Professor Kang Zhang. The editorial board members consist of an international group of leading experts in their research domains. Our mission at the editorial board is to ensure your best research is subjected to the highest quality and rigorous peer-review in a timely fashion. We also have dedicated editorial staff who co-ordinate the peer review process, production of your accepted articles and marketing of MedComm – Future Medicine. We will ensure that your paradigm-shifting discoveries will receive the highest quality production, and reach the widest readership.

MedComm – Future Medicine is born at a time of global healthcare emergency. The Covid-19 pandemic has put into focus the importance of international collaborative efforts, which have resulted in an unprecedented increase in research output. Effective review and dissemination of this information is indispensable to maximizing research impact and public engagement. MedComm – Future Medicine aspires to be at the nexus of translational research advances. The success of MedComm – Future Medicine will be a testament to the global community of scientists and researchers who contribute to the journal's contents, review process and citations. We hope you will enjoy reading our contents and consider submitting your next paradigm-shifting research findings to MedComm – Future Medicine. Together, we hope to transform the future of medicine!

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
1.00
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信